LARIMAR THERAPEUTICS INC (LRMR)

Noteworthy Monday Option Activity: AOSL, BIRK, LRMR

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

These stocks are moving in today's session

Let's take a look at the stocks that are in motion in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

On Monday, Larimar Therapeutics, Inc. (NASDAQ:LRMR) released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s Ataxia. Friedreich’s Ataxia is caused by a mutation in the FXN gene, which carries the code for the frataxin protein. Frataxin is important for the normal function of mitochondria, the energy-producing parts of cells At the time of data cut

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Which stocks are gapping on Monday?

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension...

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with...

Bullish Two Hundred Day Moving Average Cross - LRMR

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical...

LRMR Makes Bullish Cross Above Critical Moving Average

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics (LRMR) Shares Cross Below 200 DMA

Commit To Purchase Larimar Therapeutics At $5, Earn 22.7% Annualized Using Options

Commit To Purchase Larimar Therapeutics At $5, Earn 20.3% Annualized Using Options

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA)...

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare...

2 Potentially High-Reward Growth Stocks to Buy Right Now

These two biotechnology stocks could be gearing up for a run.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out as we have all of the hottest market news available on Tuesday morning!

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE)...

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Larimar Therapeutics (NASDAQ:LRMR) just reported results for the first quarter ...

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024

LRMR stock results show that Larimar Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2...

Oversold Conditions For Larimar Therapeutics (LRMR)

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Larimar Therapeutics (NASDAQ:LRMR) just reported results for the fourth quarter...